| INTRODUCTION
Antimicrobial resistance is one of the most pressing biomedical issues of the 21st century. [1] Bacteria utilize many different mechanisms to evade the effects of antibiotics, and one mechanism used by many species of bacteria is the formation of bacterial biofilms. Biofilms are defined as a surface attached community of bacteria, which are embedded within an extracellular polymeric matrix. [2, 3] The National
Institutes of Health (NIH) estimates that 80% of all bacterial infections in the human body are biofilm related, which leads to approximately 550,000 annual fatalities. [4] Residing within a biofilm state confers a large increase in the ability of bacteria to withstand antibiotics due to the extra protection provided by the extracellular matrix, increased gene transfer between colonies, and differential gene expression compared to planktonic bacteria. [4, 5] It has been established that bacteria reside in a biofilm state to better protect themselves from environmental stress or sources of eradication, which include antiseptics, antibiotics, and immune responses with studies showing that biofilm-associated bacteria can exhibit upward of 1,000 times less sensitivity to conventional antibiotics. [3, 4, 6] Mycobacterium tuberculosis is the causative agent of tuberculosis (TB) and has recently exceeded HIV as the number one cause of death of humans from an infectious disease. [7] According to the CDC, TB accounted for ~1.7 million deaths worldwide in 2016, [8] and it is believed that approximately one-third of the world's population are currently infected with M. tuberculosis. [8] These statistics are alarming due to the complexity and length of treatment along with the emergence of resistant strains. [9] The contribution of M.
tuberculosis biofilm formation on the pathogenesis of bacterial persistence and antimicrobial drug resistance remains controversial; however, during the chronic stages of a M. tuberculosis infection in humans and some animals, bacilli are released from dead cells, and colonies survive by attaching to an extracellular matrix derived by the host and pathogen. This process is similar to the survival techniques employed by biofilm-forming bacteria. Previously, we showed that in vitro culture of extracellular bacilli attached to an extracellular matrix derived from lysed host cells expressed extreme phenotypic resistance to first-line anti-TB drugs alone or in combination. Therefore, a biofilm mode of growth is thought to potentially play a role in the persistence of M. tuberculosis infections. [10, 11] Currently, the first-line treatment for drug-susceptible M. tuberculosis consists of a minimum of 2 months of antibiotic combination therapy with isoniazid (INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide (PZA) followed by an additional 4-7 months of combination therapy with INH and RIF [12, 13] to eliminate persistent reservoirs of M. tuberculosis, which can lead to a rebound infection if not completely eradicated. [11] This treatment regimen does, however, lead to patient non-compliance due to complications and toxicity associated with long-term antibiotic therapy. Our previous work has shown that M. tuberculosis biofilm communities are significantly more resistant than planktonic bacteria to treatment with isoniazid. [14] Therefore, the development of small molecules that disrupt mycobacterium biofilms may find use as adjuvants that, when paired with standard TB antibiotics, could significantly reduce the TB treatment regimens and lead to better patient compliance. Previously, we have shown that 2-aminoimidazole (2-AI) derivatives that disperse Mycobacterium smegmatis biofilms will also disperse M. tuberculosis biofilms. These compounds were shown to work synergistically with INH to effectively eradicate M. tuberculosis biofilms in an in vitro model mimicking the lesions in tuberculosis patients' lungs by employing lysed human leukocytes as a biofilm growth surface. [10] One of these active 2-AI derivatives is compound 1 (Figure 1 ), which exhibited an EC 50 value of 52.8 μm against M. smegmatis. [14] Here, the EC 50 value is defined as the concentration necessary to elicit 50% dispersion of a preformed biofilm as compared to media-onlytreated controls. Interestingly, in addition to its biofilm dispersion activity, this compound also sensitized M. tuberculosis to the effects of a certain subset of β-lactam antibiotics, effecting a 16-fold reduction in the minimum inhibitory concentration (MIC) of carbenicillin against the M. tuberculosis H37Rv laboratory strain at 31.25 μM. [15] Compound 1 also had β-lactam potentiation effects against M. smegmatis; however, they were substantially more moderate, achieving two-to fourfold reductions. Due to the precedent of activity displayed by compound 1 and other 2-AI-containing molecules, this structure activity relationship (SAR) chose to keep the 2-AI portion of the molecule consistent and use alterations of the alkyl tail portion in attempts to improve activity. Additionally, recent literature has indicated that increasing the length of alkyl chain within a pyrazinamide derivative increases potency against M. tuberculosis. [16] With this precedent and the activity exhibited by compound 1, a SAR was performed to probe what role, if any, alkyl chains play in anti-biofilm and potentiation activity. Interestingly, we find that these activities are somewhat decoupled, as the most potent antibiofilm compound and the most potent β-lactam potentiator are distinct.
| METHODS AND MATERIALS

| Broth microdilution method for MIC determination of M. smegmatis
Cultures (48 hr) were subcultured to 5 × 10 5 CFU/ml in 7H9 broth supplemented with ADC enrichment. Aliquots (1 ml) were placed in culture tubes, and compound was added from 100 mm stock samples in DMSO, such that the compound concentration equaled the highest concentration tested (200 μm). Samples were then aliquoted (200 μl) into the first row of wells of a 96-well plate, with all remaining wells being filled with 100 μl of initial bacterial subculture. Row one wells were mixed five times before 100 μl was transferred to the following row (row two). Row two was then mixed five times, and 100 μl was transferred to row three. This process provided a serial dilution of the compound and was continued until the final row had been mixed. Plates were covered with Glad Press n' Seal and were incubated under stationary conditions at 37°C for 48 hr. After 48 hr, the wells were stained with alamarBlue (Thermo Fisher) and were incubated under stationary conditions at 37°C for 8 hr. After 8 hr, the wells with bacterial growth were visualized as pink and the wells with no viable bacteria were visualized as blue. MIC values were recorded as the lowest concentration at which no bacterial growth was observed.
| Broth microdilution method for antibiotic resensitization of M. smegmatis
Cultures (48 hr) were subcultured to 5 × 10 5 CFU/ml in 7H9 broth supplemented with ADC enrichment. Aliquots (4 ml) were placed in culture tubes, and compound was added from 100 mm stock samples in DMSO, such that the compound concentration was 30% of the MIC of the compound against the particular bacterial strain. One milliliter of the resulting solution was aliquoted into a separate culture tube and was dosed with antibiotic so that the resulting concentration was the highest desirable concentration to be tested. Bacteria treated with antibiotic alone were used as a control. Row one of a 96-well plate was filled with 200 μl of the antibiotic/ compound solution, and the remaining rows were filled with 100 μl per well of the remaining 4 ml bacterial subculture. Row one wells were mixed five times before 100 μl was transferred to the following row (row two). Row two was then mixed five times, and 100 μl was transferred to row three. This process was repeated until the second to last row had been reached. The last row would have only compound and serve as a negative control. The antibiotic only treated bacteria was plated by aliquoting 200 μl of the treated bacteria into row one and filling the remaining rows with untreated bacteria from the original subculture. The rows were mixed in the same way as described above. Plates were covered with Glad Press n' Seal and were incubated under stationary conditions at 37°C for 48 hr. After 48 hr, the wells were stained with alamarBlue (Thermo Fisher) and were incubated under stationary conditions at 37°C for 8 hr. After 8 hr, the wells with bacterial growth were visualized as pink and the wells with no viable bacteria were visualized as blue. MIC values were recorded as the lowest concentration at which no bacterial growth was observed, which was determined by the blue well at the lowest concentration. Fold reductions were determined by comparison of the compound treated wells with the antibiotic only control well.
| General static dispersion assay protocols for M. smegmatis
Cultures were incubated for 48 hr and then subcultured to 0.01 in Difco M9 minimal salts media. 100 μl of the subculture was aliquoted into every well in columns 2-11 of a 96-well PVC microtiter plate. Columns 1 and 12 were left empty to serve as control wells. Plates were covered with Glad Press n' Seal and were incubated under stationary conditions at 37°C for 48 hr. After 48 hr, the media were discarded, and the plates were washed thoroughly with water. 100 μl of fresh media containing the appropriate concentration of compound was added to all of the wells in columns 2-4 and 9-11. 100 μl of sterile media was added to all of the wells in columns 1 and 12 and columns 5-8. Plates were covered with Glad Press n' Seal and were incubated under stationary conditions at 37°C for 24 hr. After 24 hr, media were discarded, and the plates were washed thoroughly with water. 110 μl of a 0.1% aqueous solution of crystal violet was added to every well, and the plates were left at ambient temperature for 30 min. After 30 min, the crystal violet was disposed, and the plates were washed thoroughly with water. 200 μl of 95% ethanol was added to each well, and the plates were left at ambient temperature for 10 min. 125 μl of the ethanol solution was transferred to a fresh polystyrene microtiter plate, and the plate was quantified by measuring the OD 540 . The percent dispersion was calculated by comparing the OD 540 of the treated wells with the OD 540 of the untreated wells, which contained only media after biofilm growth. The first and last column, which had only sterile media, were used as blanks and those values were subtracted from the OD 540 obtained in the other columns.
| RESULTS AND DISCUSSION
| Analogue synthesis
For this study, we elected to explore the SAR of the alkyl tail region of compound 1, looking at linear chains as well as branched symmetric and asymmetric chains. Compounds were synthesized utilizing the strategy outlined in Scheme 1, using the protected 2-AI 3 as the common coupling partner. The synthesis of 3 was initiated with the desymmerization of glutaric anhydride 5 to produce the gamma-keto ester 6. This intermediate was treated with oxalyl chloride to form the acid chloride, which was further reacted with diazomethane followed by the quenching with hydrobromic acid (HBr) to afford the desired α-bromo ketone 4. The 2-AI ring was then installed via Boc guanidine cyclization to yield the 2-AI 7. Finally, treatment with Boc anhydride followed by hydrogenation to remove the benzyl group yielded 2-AI 3 (Scheme 2).
With 3 in hand, all final 2-AI derivatives were synthesized by activating the carboxylic acid with HBTU, coupling with the appropriate amine, removing the Boc groups with TFA, and performing counter ion exchange to generate the HCl salt of the desired product (9A-K, 10A-G, 11A-B, 12, 13 ) (Scheme 3). All the single carbon chain amines (as well as a select number of the branched amines) were commercially available. The branched amines that were not commercially available were synthesized from the corresponding ketones through a reductive amination using ammonium acetate and sodium cyanoborohydride in anhydrous methanol (Schemes S1 and S2). The asymmetric ketones necessary to access amines for the synthesis of 12 and 13 were generated through the synthesis of the Weinreb amide followed by a Grignard addition to produce the desired ketone. The previously described reductive amination procedure was used to deliver the desired amines (Schemes S3 and S4). Despite the addition of a chiral center, enantioselectivity was not controlled or resolved during synthesis. Ultimately, this SAR study was to determine whether there was an increase or decrease in activity with the absence of symmetry in the tail portion of the molecule. If activity is observed, further studies to enhance activity by controlling enantioselectivity will be performed.
| Screening for biofilm dispersion
Initial screening focused on the ability of the compounds to induce dispersion of preformed M. smegmatis biofilms as assessed using a crystal violet reporter assay (Table  S1) . [17] Previously, we found compound 1 to have an EC 50 of 52 μm. Upon evaluation of the branched derivative library, it was revealed that lengthening the tail one carbon (10E) increased activity, with this compound exhibiting an EC 50 of 19.9 ± 5.3 μm ( Figure S1 ). Shortening the tail by one carbon Figure S2 ). Adding or removing two carbons to the tail resulted in a further decrease in activity with compounds 10C (two carbons shorter) and 10F (two carbons longer) exhibiting EC 50 values of >200 μm and 150 ± 11 μm, respectively. The single linear tails (9A-K), however, possessed limited dispersion activity. Compound 9H displayed the best dispersion activity with an EC 50 of 89.9 ± 15 μm. None of the other branched derivatives induced dispersion at 200 μm (highest concentration tested). Next, we evaluated the asymmetric derivatives that contained the most active branched tail lengths. Compound 11A, which has the same length carbon tail (seven total carbons) as the most active compound 10E, exhibited an EC 50 value of 109 ± 13 μm. The addition of one carbon in compound 11B resulted in a decrease in EC 50 value to 57.8 ± 4.6 μm, although this EC 50 was still not comparable to lead compound 1 or 10E ( Figure S3 ). With that, the synthesis efforts shifted to incorporating a phenalkyl chain to one side of the branch while keeping the other branch consistent with a linear chain of six carbons. Compounds 12 and 13 returned EC 50 values of 66.9 ± 3.0 and 85.1 ± 13 μm, respectively, which were again less active than compound 1 or 10E. The incorporation of the aryl substituents did not improve upon the activity of 10E (complete results can be found in Table S1 ).
| Screening for potentiation activity
We previously reported that compound 1 exhibits synergy with β-lactam antibiotics against planktonic M. tuberculosis. [18] Based upon this observation, these newly synthesized derivatives were screened for the ability to potentiate several cephalosporin and penicillin antibiotics against planktonic M. smegmatis. To evaluate the potentiation activity of these compounds against M. smegmatis, the MIC of antibiotics and the compounds alone were first determined. Following this determination, the MIC of each antibiotic was measured in the presence of each compound at 30% its MIC, which is the typical concentration we employ for potentiation assays. [18, 19] Interestingly, none of the symmetric branched tail compounds produced any notable reductions at this concentration. When compound 1 was tested at 50% its MIC, results were modest producing at most a 16-fold reduction in ceftazidime MIC. For the linear tail compounds at 30% MIC, activity increased slightly as the length of the tail increased, but remained modest with the largest fold reduction observed being a fourfold reduction with cefotaxime and compound 9K. Interestingly, when the asymmetric tails were analyzed, compound 11A showed no notable activity at 30% its MIC for five of the six antibiotics, but effected a 32-fold reduction in the cefotaxime MIC. Compound 11B, which was a more potent biofilm inhibitor than 11A, showed only an eightfold reduction in the MIC of cefotaxime and again no notable reduction in the MICs of the other antibiotics tested (Table 1) . Additionally, compounds 12 and 13 were screened and, again, it was seen that the less active biofilm disruptor, compound 13, was more active than the more potent antibiofilm derivative (12) , but activity was limited to two-and fourfold reductions except again in the case of cefotaxime, where the reduction was 32-fold (complete results can be found in Tables S2 and S3 ). The selectivity of this series of compounds for cefotaxime potentiation over other β-lactam antibiotics mirrors that observed with a 2-aminobenzimidazole series previously reported, which possess a pattern of selectivity distinct from direct β-lactamase inhibitors, such as clavulanic acid, and does not directly inhibit β-lactamase activity. [18] 4 | CONCLUSIONS 
